FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Goldshleger Ilya						2. Issuer Name and Ticker or Trading Symbol RxSight, Inc. [RXST]								(Check all appli		,		10% Ov	vner	
(Last) (First) (Middle) C/O RXSIGHT, INC.					3. Date of Earliest Transaction (Month/Day/Year) 08/05/2024								V	below			Other (s below)	вреспу		
100 COL	UMBIA					4. If	Amend	ment, I	Date	of Ori	ginal F	Filed (Month/	Day/Yea		ine)		· Joint/Group	·		
(Street) ALISO V	VIEJO CA 92656												V	Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(:	State)	(Z	ip)		Rι	ıle 10)b5-	1(c)) Tra	ansa	action In	dicat	ion						
						V	Check t satisfy t	his box he affirr	to ind	licate t e defer	hat a tr	ransaction was aditions of Rule	s made p e 10b5-1(ursuant to a c). See Inst	contra	ct, instru 10.	uction or writte	en plan	that is inter	nded to
			Table	l - N	Ion-Deriva	tive	Secu	rities	Ac	quir	ed, D	isposed	of, or	Benefic	ially	Own	ed			
Date				2. Transaction Date (Month/Day/Ye	2A. Deeme Execution if any (Month/Da		n Date	, [3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			nd 5) Securities Beneficial Owned Fo		ities icially d Following	Form: (D) or Indire	Direct	7. Nature of Indirect Beneficial Ownership	
									7	Code	v	Amount	(A) or (D)	Price			ted action(s) 3 and 4)	(Instr.	4)	(Instr. 4)
Common	Stock				08/05/202	4				S ⁽¹⁾		1,145	D	\$38.80	11(2)	5	0,101		D	
Common	Stock				08/05/202	4				S ⁽¹⁾		1,855	D	\$39.42	58(3)	4	8,246		D	
Common	Stock				08/05/202	4				S ⁽¹⁾		1,087	D	\$38.82	89(4)	4	7,159		D	
Common	Stock				08/05/202	4				S ⁽¹⁾		1,913	D	\$39.512	28(5)	4	5,246		D	
Common	Stock				08/05/202	4				S ⁽¹⁾		1,827	D	\$39.042	29(6)	4	3,419		D	
Common	Stock				08/05/202	4				S ⁽¹⁾		1,173	D	\$39.72	93 ⁽⁷⁾	4	2,246		D	
Common Stock														1	1,372			By spouse		
			Tab	le I	I - Derivati (e.g., pu							sposed of s, convert				wne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversio or Exercis Price of Derivative Security		· · · ·	Exec if an	Deemed cution Date, y tth/Day/Year)		action (Instr.	5. Nu of Deriv Secu Acqu (A) or Dispo of (D) (Instrand 5	ative rities ired sed	Exp (Mo	iration nth/Da	y/Year)	Amo Seci Und Deri Seci 3 an	Amount or Number of	Deri Sec (Ins	rice of vative urity tr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	/ OF D O (I	0. Ownership orm: Direct (D) r Indirect) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

- 1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person.
- 2. Represents the weighted average share price of an aggregate total of 1,145 shares sold in the price range of \$38.00 to \$38.99 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 3. Represents the weighted average share price of an aggregate total of 1,855 shares sold in the price range of \$39.11 to \$40.095 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 4. Represents the weighted average share price of an aggregate total of 1,087 shares sold in the price range of \$38.00 to \$38.99 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 5. Represents the weighted average share price of an aggregate total of 1,913 shares sold in the price range of \$39.13 to \$40.095 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 6. Represents the weighted average share price of an aggregate total of 1,827 shares sold in the price range of \$38.43 to \$39.42 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 7. Represents the weighted average share price of an aggregate total of 1,173 shares sold in the price range of \$39.45 to \$40.095 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Remarks:

Exhibit 24 - Power of Attorney; Co-President and Chief Operating Officer

/s/ Shelley Thunen, as Attorney-in-Fact

08/06/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in	n this form are not required to respond	unless the form displays a currently valid	OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Ron Kurtz, Shelley Thunen, Martin J. Waters, Robert L. Wernli, Jr., Michael Brito-Stamm, Mahnaz Dodge and Bridget Balisy, or either of them acting singly, and with full power of substitution and re-substitution, the undersigned's true and lawful attorney-in-fact (each of such persons and their substitutes being referred to herein as the "Attorney-in-Fact"), with full power to act for the undersigned and in the undersigned's name, place and stead, in any and all capacities, to:

- 1. Prepare, execute and submit to the Securities and Exchange Commission ("SEC"), RxSight, Inc. (the "Company"), and/or any national securities exchange on which the Company's securities are listed any and all reports (including any amendments thereto) the undersigned is required to file with the SEC, or which the Attorney-in-Fact considers it advisable to file with the SEC, under Section 13 or Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act") or any rule or regulation thereunder, or under Rule 144 under the Securities Act of 1933 ("Rule 144"), with respect to the any security of the Company, including Forms 3, 4 and 5, Schedules 13D and 13G, and Forms 144; and
- 2. Obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the Company's equity securities from any third party, including the Company and any brokers, dealers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such third party to release any such information to the Attorney-in-Fact.

The undersigned acknowledges that:

- a) This Power of Attorney authorizes, but does not require, the Attorney-in-Fact to act in his or her discretion on information provided to such Attorney-in-Fact without independent verification of such information;
- b) Any documents prepared or executed by the Attorney-in-Fact on behalf of the undersigned pursuant to this Power of Attorney will be in such form and will contain such information as the Attorney-in-Fact, in his or her discretion, deems necessary or desirable;
- c) Neither the Company nor the Attorney-in-Fact assumes any liability for the undersigned's responsibility to comply with the requirements of Section 13 or Section 16 of the Exchange Act or Rule 144, any liability of the undersigned for any failure to comply with such requirements, or any liability of the undersigned for disgorgement of profits under Section 16(b) of the Exchange Act; and
- d) This Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under Section 13 or Section 16 of the Exchange Act, including, without limitation, the reporting requirements under Section 13 or Section 16 of the Exchange Act.

The undersigned hereby grants to the Attorney-in-Fact full power and authority to do and perform each and every act and thing requisite, necessary or advisable to be done in connection with the foregoing, as fully, to all intents and purposes, as the undersigned might or could do in person, hereby ratifying and confirming all that the Attorney-in-Fact, or his or her substitute or substitutes, shall lawfully do or cause to be done by authority of this Power of Attorney.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 4 or 5 or Schedules 13D or 13G or Forms 144 with respect to the undersigned's holdings of and transactions in securities of the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Attorney-in-Fact. This Power of Attorney revokes all previous powers of attorney with respect to the subject matter of this Power of Attorney.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed on June 13, 2024.

Signature: /s/ Ilya Goldshleger

Print Name: Ilva Goldshleger

